SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

To answer your good questions.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
falconer66a Member Profile
 
Followed By 51
Posts 419
Boards Moderated 0
Alias Born 01/29/04
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/14/2017 5:15:55 PM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 8/11/2017 5:22:15 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/11/2017 4:42:04 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/7/2017 4:41:07 PM
Anavex Reports Fiscal Third Quarter 2017 Financial Results "GlobeNewswire Inc." - 8/7/2017 7:00:00 AM
Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board "GlobeNewswire Inc." - 7/20/2017 7:00:00 AM
Pharmaceutical Leaders Pave the Way to New Alzheimer’s Treatments "NetworkNewsWire" - 6/15/2017 7:00:00 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 6/13/2017 6:03:09 AM
Anavex Life Sciences to Present at Jefferies 2017 Global Healthcare Conference "GlobeNewswire Inc." - 6/5/2017 7:00:00 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 5/26/2017 4:32:21 PM
Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome: Data Prese... "GlobeNewswire Inc." - 5/22/2017 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/15/2017 5:54:40 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 5/15/2017 5:54:40 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/10/2017 4:29:05 PM
Anavex Reports Fiscal Second Quarter 2017 Financial Results "GlobeNewswire Inc." - 5/10/2017 7:00:00 AM
Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs "GlobeNewswire Inc." - 5/1/2017 7:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 4/21/2017 6:09:35 AM
Positive News in the Fight against Cancer Fuels Quest for More Good Tidings "NetworkNewsWire" - 4/18/2017 8:45:00 AM
Anavex Life Sciences Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor "GlobeNewswire Inc." - 4/3/2017 7:00:00 AM
Anavex Life Sciences Reports Dismissal of Appeal in the Cortina Lawsuit "GlobeNewswire Inc." - 3/30/2017 8:00:00 AM
Anavex Life Sciences to Present at the 13th International Conference on Alzheimer's and Parkinson's Diseases AD/PD™ 2017 "GlobeNewswire Inc." - 3/29/2017 8:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 3/17/2017 6:06:45 AM
Anavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference "GlobeNewswire Inc." - 3/15/2017 7:00:00 AM
Anavex Life Sciences to Present at 14th Annual BIO Asia International Conference "GlobeNewswire Inc." - 3/13/2017 7:00:00 AM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 3/10/2017 7:17:05 AM
falconer66a   Wednesday, 04/26/17 10:18:09 AM
Re: jimmy667 post# 102972
Post # of 115864 
To answer your good questions.

Yes, additional human trials are needed, for several reasons. A conventional double-blind Phase 3 study, with an experimental arm (with the real Anavex 2-72), and a control arm, where a physically identical placebo is administered is needed. FDA rules require such for eventual drug approval. FDA is “protecting us.” They want to be as certain as possible that adverse events (side effects) are minimal and not disqualifying, and that the drug actually works, with regulatory efficacy. The previous Phase 1/Phase 2 study is inadequate for all of this — a matter I do not contest in any way.

My point is this. The existing murine and P1/P2 data, coupled with an understanding of how Anavex 2-73 restores normalized neuron function (its hard cellular biochemistry) all predict a very successful Phase 3 trial. The chances that the drug will prove non-effective in stabilizing or reducing Alzheimer’s symptoms, and/or prove to have disqualifying adverse events are, to me, infinitesimally tiny. Hence, I’m confident in the appreciating value of my early equity position in AVXL. Wish I could buy more shares.

You mentioned the heretofore unconsidered factors of insomnia relief and quality of life outcomes for both patients and care givers. I would add the many additional conditions Anavex pipeline drugs will treat; from cancers, psychiatric conditions, heart disease, to epilepsy, and a growing number of others. All of that will play out so favorably in coming years, for both patients and Anavex Life Sciences, I’m certain.

The magnitude of the Anavex medical revolution is unappreciated by most. Few are able to envision it, for several reasons. Commonly, Anavex’s Alzheimer’s approach is erroneously conflated and mixed with the dozens of failed amyloid suppression or removal trials of other drug companies. They all fail; therefore, Anavex 2-73 is likewise destined for expensive clinical failures, too.

Many others fail to understand Anavex 2-73's unique biochemistry and its ability to restore normal cell function. Too good to be true. Appears to be a mystical nostrum. Can’t be true, as future clinical trials will prove (so they think).

Then, Anavex Life Sciences is a pharmaceutical start-up, with no proven revenues, without even an FDA-approved product. The record for such companies mandates a very harsh assessment regarding any retail equity position. Therefore, it’s regarded as a long and potentially bad gamble by so many “experts,” both financial and scientific.

You mentioned the assessment of a placebo effect as a potential cause of clinical efficacy. Not a factor. Not a consideration. No one, ever, has been able to suppress or reverse the multitude of Alzheimer’s symptoms by willful or hopeful thinking.

Anavex Life Sciences and Anavex 2-73 are the real things.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist